Literature DB >> 9809361

Chondrocalcinosis is a feature of Gitelman's variant of Bartter's syndrome. A new look at the hypomagnesemia associated with calcium pyrophosphate dihydrate crystal deposition disease.

L Punzi1, L Calò, F Schiavon, M Pianon, M Rosada, S Todesco.   

Abstract

The occurrence of chondrocalcinosis in patients with Bartter's syndrome has been reported as a typical example of hypomagnesemia-associated calcium pyrophosphate dihydrate crystal (CPPD) deposition disease. However, hypomagnesemia is a feature of Gitelman's variant of Bartter's syndrome, whereas serum magnesium levels are normal in Bartter's syndrome strictly speaking. We managed four patients with chondrocalcinosis and hypomagnesemia who met criteria for Gitelman's disease, including hypomagnesemia, hypokalemia with normal or high urinary potassium excretion, hypocalciuria, and normal blood pressure. Based on our experience with these patients, we argue that many cases of chondrocalcinosis and hypomagnesemia ascribed in previously published articles to Bartter's syndrome were due to Gitelman's syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809361

Source DB:  PubMed          Journal:  Rev Rhum Engl Ed        ISSN: 1169-8446


  7 in total

Review 1.  Clinical trials review: crystal deposition diseases.

Authors:  R A Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

2.  Pseudogout, hypomagnesemia, and liver transplantation.

Authors:  Robert Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

Review 3.  Calcium Pyrophosphate Deposition Disease.

Authors:  Ann K Rosenthal; Lawrence M Ryan
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

Review 4.  Magnesium disorders can cause calcium pyrophosphate deposition disease: A case report and literature review.

Authors:  Akanksha Joshi; Chokkalingam Siva
Journal:  Eur J Rheumatol       Date:  2017-08-29

5.  Treatment and management of pseudogout: insights for the clinician.

Authors:  Paul Macmullan; Geraldine McCarthy
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

Review 6.  Comorbidities in patients with crystal diseases and hyperuricemia.

Authors:  Sebastian E Sattui; Jasvinder A Singh; Angelo L Gaffo
Journal:  Rheum Dis Clin North Am       Date:  2014-02-19       Impact factor: 2.670

Review 7.  Molecular Basis, Diagnostic Challenges and Therapeutic Approaches of Bartter and Gitelman Syndromes: A Primer for Clinicians.

Authors:  Laura Nuñez-Gonzalez; Noa Carrera; Miguel A Garcia-Gonzalez
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.